Why Janux Therapeutics Stock Soared as the Market Sagged Today

One of the hotter biotech companies on the scene might be changing owners before long.Clinical-stage biotech Janux Therapeutics (JANX 11.47%) was a standout title on a gloomy Wednesday stock market. As investors fretted about an unfavorable inflation report from the federal government, bulls piled into the company's shares on a report that it might be for sale. As a result, it closed the day almost 12% higher in price, contrasting very sharply with the nearly 1% decline of the bellwether S&P 500 index.Hangi ...